Janssen announced results from two Phase 3 studies demonstrating that simeprevir led to sustained virologic response in 80% of treatment-naïve genotype 1 chronic hepatitis C adult patients with compensated liver disease when administered once daily with pegylated interferon and ribavirin.
Sucampo Pharmaceuticals Inc. and Takeda Pharmaceuticals said that they received U.S. regulatory to market their constipation treatment Amitiza for a new use. The Food and Drug Administration approved the pill for constipation caused by opioid pain medications used by patients with non-cancer chronic pain.
Forest Laboratories Inc.'s fiscal fourth-quarter earnings plunged 76%, as the drug developer's revenue continued to take a hit from a key patent loss. The New York company said that it earned almost $150 million less this quarter than a year earlier.
An investigational treatment for an inherited form of Lou Gehrig’s disease has passed an early phase clinical trial for safety. The researchers have shown that the therapy produced no serious side effects in patients with the disease, also known as amyotrophic lateral sclerosis.
For children who have had HIV-1 infection since birth, the combination drug therapies now used to treat HIV appear to protect against the heart damage seen before combination therapies were available, according to researchers in a National Institutes of Health network study.
An analyst has upgraded his outlook for AbbVie Inc., expecting greater sales of the company's blockbuster anti-inflammatory drug Humira and several experimental products. He thinks AbbVie shares will trade higher as the company continues to report progress for its drugs in clinical development.
Medicyte has signed a licensing agreement for the rights to use Lentiviral vector technology from Life Technologies to develop and market next generation, cell-based upcyte cell products to the biopharma and academic research markets.
Integrated DNA Technologies launches an enhanced version of the open access PrimerQuest online tool, for efficient PCR primer and probe design. Selection parameters have been optimized with built-in presets for a diverse range of applications, to produce the very best primers and probes.
The NEXTflex 16S V4 Amplicon-Seq Kit has been developed to simplify bacterial metagenomics studies using Illumina HiSeq and MiSeq platforms. This kit allows users to go from sample to sequence in two hours, making it the fastest library prep kit available.
Unavoidable damage caused to the heart and lungs by radiotherapy treatment of tumors in the chest region can be limited by the administration of an ACE inhibitor, a drug commonly used in the treatment of cardiovascular disease, a group of Dutch researchers have found.
A massive study analyzing gene expression data from 22 tumor types has identified multiple metabolic expression changes associated with cancer. The analysis also identified hundreds of potential drug targets that could cut off a tumor’s fuel supply or interfere with its ability to synthesize essential building blocks.
The board of Irish drugmaker Elan has unanimously rejected a takeover bid from Royalty Pharma, saying the U.S. investment company's offer of $11.25 a share is much too low. Royalty last week lowered its bid for Elan from an original $12 per share offer.
Merck and Bristol-Myers Squibb will run a mid-stage clinical trial of a drug regimen designed to treat the most common type of the hepatitis C virus. The trial will study a combination of Bristol's drug daclatasvir, and Merck's MK-5172.
Researchers have devised an way to block biological signaling pathways that, when overactive, lead to many types of cancers. They've done so by disrupting the function of a mediator, or scaffold, protein that brings together key members of the pathway and promotes their interaction to stimulate cell growth and division.
EMD Serono Inc. announced the continued expansion of the company's presence in the United States, resulting in an estimated 20% increase in EMD Serono's employee base from last July to the end of 2014. The expansion will primarily take place at the site in Billerica, Mass.